Metabolism and function · 20 October 2026
Phosphate, kidneys and ageing: what the mouse experiment can tell us
A genetic rescue experiment raises an important mineral-regulation question, but does not establish a universal low-phosphate diet.
An essential substance can still require regulation
Phosphate is involved in energy transfer and cellular structure. That makes its regulation relevant to a discussion of metabolism, but it does not mean that more is always better—or that a harmful excess makes the nutrient unnecessary. The question is what happens when intake, handling and physiological needs are out of balance.
For EPK, the connection is a limit on calorie-only explanations. Adequate energy is one part of maintaining function. The proposed energy-per-kilogram framework must also account for the possibility that organ function and nutrient handling change what a person needs.
The mouse experiment
Ohnishi and Razzaque used mice lacking Klotho and altered the phosphate transporter NaPi2a. Lower circulating phosphate in the double-mutant mice accompanied improvement in several abnormalities; a high-phosphate diet restored adverse features. The dietary comparison used 0.6% versus 1.2% phosphate. This combination of genetic change and dietary reversal strengthens a causal argument within the model. [1]
The survival groups contained 17, 23, 15 and 7 animals. Observation ended at twenty weeks: survival through that endpoint is not a demonstration of a normal lifespan. These genetically altered mice cannot establish a harmful dietary threshold for healthy adults. Calcium, vitamin D and renal physiology also complicate translation. [1]
What the human experiment adds
Mohammad and colleagues randomised twenty young adults with normal kidney function to increased phosphate or a lower-phosphate condition using a phosphate binder, with sodium controlled. The higher-phosphate condition raised blood pressure and pulse. The protocol also included a later vitamin D intervention. It was a short physiological experiment, not a trial of disease incidence or lifespan. [2]
This provides a human reason to investigate phosphate regulation, but the comparison was not simply two ordinary diets. A binder-containing control, supplementation and the small sample affect how confidently it can inform everyday food choices.
A separate acute experiment found that a high phosphate dose impaired endothelial function but did not increase the blood-pressure response to handgrip exercise or isolated muscle metaboreflex activation. Different outcomes did not all move in the same direction. [3]
Avoid converting a mechanism into a food blacklist
The mouse result does not justify removing broad food groups or assuming all phosphorus-containing foods have the same effect. Nor does a controlled supplement comparison show that every meal containing phosphate creates the same physiological exposure.
A useful dietary investigation would distinguish food sources and additives, record the rest of the diet, and assess kidney function. It would also ask what replaces a removed food. An intervention that changes phosphate along with protein, calcium and energy cannot attribute every outcome to phosphate alone.
Similarly, a finding in healthy young adults is not a treatment instruction for someone with kidney disease. The research question must specify the population rather than treat “phosphate intake” as having one meaning across all health states.
A better EPK research question
The useful link to the functional-capacity working paper is contextual: do differences in nutrient regulation help explain why similar energy intakes do not guarantee similar function? This is a proposal for investigation, not evidence that phosphate validates EPK.
A first human study could assess dietary sources, kidney function and relevant biochemical measurements alongside intake, mass and function. A later intervention would need an appropriate comparator, adequate nutrition in both groups and a prespecified outcome. Blood pressure, physical function and long-term disease are separate endpoints; improvement in one should not be relabelled as proof of improved longevity.
The general nutrient-adequacy theme in the books fits this question, but this article introduces a separate line of evidence rather than claiming the mouse study was already established by the books.
What we can take forward
The strongest conclusion is that disrupted phosphate handling can be an important part of disease in a particular experimental system. Small human interventions make the question worth pursuing, while also showing why outcome and exposure details matter.
That is enough to justify an EPK research-library entry and a carefully framed article. It is not enough to prescribe a universal intake restriction or promise that lowering phosphate will slow ageing. The next step is better human evidence with nutritional adequacy and renal function built into the design.
Related EPK articles
Research and guidance
Explore more studies in the research library.
- Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010. doi:10.1096/fj.09-152488. Full text reviewed.
- Mohammad J, et al. A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects. J Am Soc Nephrol. 2018;29:2089–2098.
- Effect of acute high-phosphate intake on muscle metaboreflex activation and vascular function. 2019.
Related working papers
Read the relevant PDFs: EPK–001 to 007 are the revised version 1.2 papers; EPK–008 to 010 are version 1.0 supplements. Earlier PDFs and DOI records remain on the paper archive.